Methodology for Quantitative Rapid Multi-Tracer PET Tumor Characterizations

Positron emission tomography (PET) can image a wide variety of functional and physiological parameters in vivo using different radiotracers. As more is learned about the molecular basis for disease and treatment, the potential value of molecular imaging for characterizing and monitoring disease status has increased. Characterizing multiple aspects of tumor physiology by imaging multiple PET tracers in a single patient provides additional complementary information, and there is a significant body of literature supporting the potential value of multi-tracer PET imaging in oncology. However, imaging multiple PET tracers in a single patient presents a number of challenges. A number of techniques are under development for rapidly imaging multiple PET tracers in a single scan, where signal-recovery processing algorithms are employed to recover various imaging endpoints for each tracer. Dynamic imaging is generally used with tracer injections staggered in time, and kinetic constraints are utilized to estimate each tracers' contribution to the multi-tracer imaging signal. This article summarizes past and ongoing work in multi-tracer PET tumor imaging, and then organizes and describes the main algorithmic approaches for achieving multi-tracer PET signal-recovery. While significant advances have been made, the complexity of the approach necessitates protocol design, optimization, and testing for each particular tracer combination and application. Rapid multi-tracer PET techniques have great potential for both research and clinical cancer imaging applications, and continued research in this area is warranted.

[1]  K. Någren,et al.  Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  J. Hoffman,et al.  Comparison of 18F-Fluorodeoxyglucose and 18F-Fluorothymidine PET in Differentiating Radiation Necrosis From Recurrent Glioma , 2012, Clinical nuclear medicine.

[3]  H. Minn,et al.  Pharmacokinetics of [18F]FETNIM: a potential marker for PET. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Nobuyuki Oyama,et al.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  David J. Yang,et al.  Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. , 1995, Radiology.

[6]  P. Vaupel,et al.  Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. , 2000, International journal of oncology.

[7]  K Kubota,et al.  From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.

[8]  E. Nitzsche,et al.  Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? , 1998, Radiology.

[9]  K. Ishiwata,et al.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  I. Lemahieu,et al.  Noise properties of simultaneous dual tracer PET imaging , 2005, IEEE Nuclear Science Symposium Conference Record, 2005.

[11]  Kenneth A Krohn,et al.  Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.

[12]  C Burger,et al.  Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Robert B Livingston,et al.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Zheng Fu,et al.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  S. Larson Positron Emission Tomography-Based Molecular Imaging in Human Cancer , 2004, Clinical Cancer Research.

[16]  K J Kearfott,et al.  Feasibility of simultaneous and sequentially administered dual tracer protocols for measurement of regional cerebral haematocrit using positron emission tomography. , 1990, Physics in medicine and biology.

[17]  H. Schirrmeister,et al.  [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? , 2004, The Journal of thoracic and cardiovascular surgery.

[18]  Hinako Toyama,et al.  Simultaneous quantification of two brain functions with dual tracer injection in PET dynamic study , 2004 .

[19]  H. Friess,et al.  Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  J Nucl Med , 2010 .

[21]  Huafeng Liu,et al.  Dynamic Dual-Tracer PET Reconstruction , 2009, IPMI.

[22]  Luc Thiberville,et al.  Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  A. Thiel,et al.  11C-methionine PET for differential diagnosis of low-grade gliomas , 1998, Neurology.

[24]  Andrew J. Reader,et al.  Simultaneous water activation and glucose metabolic rate imaging with PET , 2011, 2011 IEEE Nuclear Science Symposium Conference Record.

[25]  M. Spieth,et al.  A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  D. Mankoff,et al.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. , 2000, Neoplasia.

[27]  Robert B Livingston,et al.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Takuya Hayashi,et al.  Influence of residual oxygen-15-labeled carbon monoxide radioactivity on cerebral blood flow and oxygen extraction fraction in a dual-tracer autoradiographic method , 2009, Annals of nuclear medicine.

[29]  M E Phelps,et al.  An investigation of a double-tracer technique for positron computerized tomography. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  R. Boellaard,et al.  Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Tomio Inoue,et al.  A shifting landseape: What will be next FDG in PET oncology? , 2002, Annals of nuclear medicine.

[32]  B. Christian,et al.  A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[33]  Bastien Guerin,et al.  Simultaneous Dual Tracer PET Using Generalized Factor Analysis of Dynamic Sequences , 2006 .

[34]  J. Konishi,et al.  Double-injection FDG method to measure cerebral glucose metabolism twice in a single procedure , 2001, Annals of nuclear medicine.

[35]  D E Kuhl,et al.  Dual-[11C]Tracer Single-Acquisition Positron Emission Tomography Studies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  R. Boellaard,et al.  Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET , 2011, The Journal of Nuclear Medicine.

[37]  Hiroshi Watabe,et al.  Separation of input function for rapid measurement of quantitative CMRO2 and CBF in a single PET scan with a dual tracer administration method , 2007, Physics in medicine and biology.

[38]  Robert A Koeppe,et al.  Signal Separation and Parameter Estimation in Noninvasive Dual-Tracer PET Scans using Reference-Region Approaches , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  Y. Nishiyama,et al.  Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers , 2011, Molecular Imaging and Biology.

[40]  R. Moore,et al.  Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  M. Graham Combined 18F-FDG-FDOPA tumor imaging for assessing response to therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  Robert A. Koeppe,et al.  Temporally Overlapping Dual-Tracer PET Studies , 1998 .

[43]  P. Price,et al.  Clinical measurement of blood flow in tumours using positron emission tomography: a review. , 2002, Nuclear medicine communications.

[44]  R. Frackowiak,et al.  Quantitative Measurement of Regional Cerebral Blood Flow and Oxygen Metabolism in Man Using 15O and Positron Emission Tomography: Theory, Procedure, and Normal Values , 1980, Journal of computer assisted tomography.

[45]  A. Shields,et al.  PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  David J. Yang,et al.  Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  L. Thiberville,et al.  (FLT), and hypoxia with 18 fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A pilot study , 2011 .

[48]  J. Ballinger,et al.  Imaging hypoxia in tumors. , 2001, Seminars in nuclear medicine.

[49]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[50]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[51]  D. Pareto,et al.  Simultaneous Dual-tracer PET Imaging of the Rat Brain and its Application in the Study of Cerebral Ischemia , 2011, Molecular Imaging and Biology.

[52]  D.J. Kadrmas,et al.  Feasibility of rapid multitracer PET tumor imaging , 2004, IEEE Transactions on Nuclear Science.

[53]  A. Reader,et al.  Imaging apoptosis in vivo using 124I-annexin V and PET. , 2005, Nuclear medicine and biology.

[54]  R. Langer,et al.  Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer , 2011, Annals of Surgical Oncology.

[55]  J. Eary,et al.  Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  Mark Muzi,et al.  18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  A Celler,et al.  Dual-isotope PET using positron-gamma emitters , 2011, Physics in medicine and biology.

[58]  Jiahe Tian,et al.  Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[59]  M. Phelps,et al.  Quantitating tumor glucose metabolism with FDG and PET. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  Dan J Kadrmas,et al.  Single-scan dual-tracer FLT+FDG PET tumor characterization , 2013, Physics in medicine and biology.

[61]  K Wienhard,et al.  F-Dopa as an amino acid tracer to detect brain tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  R. Wahl,et al.  FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  Michael J. Morris,et al.  11C-acetate PET imaging in prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  M J Welch,et al.  Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  A. Gjedde,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[66]  D. Kadrmas,et al.  Rapid Multi-Tracer PET Tumor Imaging With $^{18}{\hbox {F-FDG}}$ and Secondary Shorter-Lived Tracers , 2009, IEEE Transactions on Nuclear Science.

[67]  Tove Grönroos,et al.  Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  Scott McJames,et al.  Evaluation of rapid dual-tracer 62Cu-PTSM + 62Cu-ATSM PET in dogs with spontaneously occurring tumors , 2008, Physics in medicine and biology.

[69]  M. Welch,et al.  PET imaging of hypoxia. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[70]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[71]  V. Oikonen,et al.  Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[73]  Y. Nishiyama,et al.  Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. , 2008, European journal of nuclear medicine and molecular imaging.

[74]  Manjit,et al.  Neurology , 1912, NeuroImage.

[75]  H. Fukuda,et al.  Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue , 1999, European Journal of Nuclear Medicine.

[76]  E. Pauwels,et al.  Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas. , 2001, Journal of cancer research and clinical oncology.

[77]  Chi-Lai Ho,et al.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  H. Minn,et al.  Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET , 2001 .

[79]  E. Nitzsche,et al.  Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. , 2001, Radiology.

[80]  A. D. Roberts,et al.  PET Measurement of rCBF in the presence of a neurochemical tracer , 2004, Journal of Neuroscience Methods.

[81]  K. Någren,et al.  Comparative double-tracer whole-body autoradiography: uptake of 11C-, 18F- and 3H-labeled compounds in rat tumors. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[82]  E. Pauwels,et al.  Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. , 2001, Journal of cancer research and clinical oncology.

[83]  D J Kadrmas,et al.  Rapid dual-tracer PTSM+ATSM PET imaging of tumour blood flow and hypoxia: a simulation study , 2006, Physics in medicine and biology.

[84]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[85]  Koen Van Laere,et al.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[86]  K. Leenders,et al.  Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET , 1995, Journal of the Neurological Sciences.

[87]  D. Kadrmas,et al.  Rapid Multi-Tracer PET Tumor Imaging With F-FDG and Secondary Shorter-Lived Tracers. , 2009, IEEE transactions on nuclear science.

[88]  M. Parliament,et al.  Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  M. Knopp,et al.  Special techniques for imaging blood flow to tumors. , 2002, Cancer journal.

[90]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[91]  Karl Herholz,et al.  18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[92]  Janet F. Eary,et al.  Positron emission tomography: imaging tumor response , 2000, European Journal of Nuclear Medicine.

[93]  Hiroshi Watabe,et al.  Rapid Quantitative Measurement of CMRO2 and CBF by Dual Administration of 15O-Labeled Oxygen and Water During a Single PET Scan—a Validation Study and Error Analysis in Anesthetized Monkeys , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[94]  Jiahe Tian,et al.  A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-18F-Fluorothymidine and 18F-FDG , 2008, Journal of Nuclear Medicine.

[95]  R. Boellaard,et al.  Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib , 2012, European Journal of Nuclear Medicine and Molecular Imaging.